TCRX TScan Therapeutics, Inc.
$0.19▲ +1.21%
Healthcare
Other
Volume 539.7K
Avg Volume (10D) 543.4K
Key Metrics & Fundamentals
Market Cap
$13.01M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.18 - 2.28
% vs 50 MA
-51.32%
% vs 200 MA
-77.83%
RSI-14
26.6
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.65
Free Cash Flow
-$28.03M
Gross Rev
$1.05M
Gross Profit
$1.05M
EBITDA
-$28.96M
COGS
–
Operating Exp
$31.54M
Operating Income
-$30.49M
EBIT
-$30.49M
Pretax Income
-$30.36M
Net Income
-$30.36M
EPS (Diluted)
-0.23
Price & Volume History
Loading chart…
Recent News
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
BioPharma Dive · Sep 4, 2026 5:00 AM ET
TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program
InvestorsHub · Sep 2, 2026 8:30 AM ET
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
GlobeNewswire · Sep 2, 2026 7:00 AM ET
Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?
Simply Wall St. · Aug 26, 2026 3:08 PM ET
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 12, 2026 8:10 AM ET
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 12, 2026 7:00 AM ET
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Zacks · Aug 6, 2026 9:50 AM ET
Cell and gene therapy manufacturers turn to specialist automation partners
Pharmaceutical Technology · Jul 31, 2026 6:17 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TCRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.